[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [62b0e3d54029...] --------------------------------------------------------------- [The "Green Revolution" Creates Massive Opportunity For Investors]( [Read this free report now.]([aff_i?offer_...] --------------------------------------------------------------- August 10, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [5X Potential Growth By 2030? Is This Little-Known Market About To Explode?]( [2b21c224-d46...](It's used for our BELOVED Air Force's fighter jets, cell phones, and wind turbines. And soon, you're going to hear about it everywhere... because according to renowned intelligence reports... [Demand Will EASILY 5X By 2030! (Discover It HERE!)]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Verona Pharma, VRNA]( Recent Analyst Action: Edward Nash, analyst at Canaccord Genuity, reiterates coverage on [Verona Pharma (VRNA)](in the Healthcare sector with a Buy rating (1 day ago). - Recent Price: $10.75 - Average Analyst Price Target: $24.00 (123.26%) - Market Cap: $605.49M [TipRanks.com]( also reports that [Verona Pharma](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.00. The target pricing ranges from a high forecast of $25.00 down to a low forecast of $23.00. [Verona Pharma (VRNA)](’s last closing price was $10.75 which would put the average price target at $24.00. Here are 3rd party ratings for [VRNA](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 31% (78 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Inflation Is a Monstrous Liability]( Grocery bills are out of control. Gas prices are sky high. All over the country, we're seeing derailed retirement plans and squeezed lifestyles. And make no mistake, government officials aren't coming to save you. You've seen what happens when they try. So… if folks want to prosper and protect their hard-earned wealth from the ravages of inflation, they MUST take matters into their own hands … and quickly. [Click to watch this special video presentation]( //trailer.web-view.net/Links/0X662838FF607C6A0079D7656BC20D38BB24D9273CF4BA4289937818C456B91FE44F84DADC5E6E509FCB184BE91E263B9E67C9223523E97B49001B444F7491C4D0F598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Aerie Pharma, AERI]( Recent Analyst Action: Oren Livnat, analyst at H.C. Wainwright, reiterates coverage on [Aerie Pharma (AERI)](in the Healthcare sector with a Buy rating and a price target of $20 (2 days ago). - Recent Price: $11.46 - Average Analyst Price Target: $15.33 (33.77%) - Market Cap: $546.04M [TipRanks.com]( also reports that [Aerie Pharma](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $15.33. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $12.00. [Aerie Pharma (AERI)](’s last closing price was $11.46 which would put the average price target at $15.33. Here are 3rd party ratings for [AERI](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Strong Buy, Top 34% (86 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Selecta Biosciences, SELB]( Recent Analyst Action: Uy Ear, analyst at Mizuho Securities, reiterates coverage on [Selecta Biosciences (SELB)](in the Healthcare sector with a Buy rating and a price target of $8 (6 days ago). - Recent Price: $2.62 - Average Analyst Price Target: $6.75 (157.63%) - Market Cap: $388.63M [TipRanks.com]( also reports that [Selecta Biosciences](currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.75. The target pricing ranges from a high forecast of $8.00 down to a low forecast of $4.00. [Selecta Biosciences (SELB)](’s last closing price was $2.62 which would put the average price target at $6.75. Here are 3rd party ratings for [SELB](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Top 31% (78 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast: ["Prepare for Five Years of Famine"]( [Screen+Shot+...]( [Click here]( for the name of the one ticker you need to protect yourself.[5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Jounce Therapeutics, JNCE]( Recent Analyst Action: Swayampakula Ramakanth, analyst at H.C. Wainwright, reiterates coverage on [Jounce Therapeutics (JNCE)](in the Healthcare sector with a Buy rating and a price target of $11 (5 days ago). - Recent Price: $5.26 - Average Analyst Price Target: $9.00 (71.10%) - Market Cap: $249.07M [TipRanks.com]( also reports that [Jounce Therapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $9.00. The target pricing ranges from a high forecast of $11.00 down to a low forecast of $7.00. [Jounce Therapeutics (JNCE)](’s last closing price was $5.26 which would put the average price target at $9.00. Here are 3rd party ratings for [JNCE](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 34% (86 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Atara Biotherapeutics, ATRA]( Recent Analyst Action: Unknown Analyst, analyst at Goldman Sachs, reiterates coverage on [Atara Biotherapeutics (ATRA)](in the Healthcare sector with a Sell rating and a price target of $3 (1 day ago). - Recent Price: $4.645 - Average Analyst Price Target: $20.38 (338.75%) - Market Cap: $438.07M [TipRanks.com]( also reports that [Atara Biotherapeutics](currently has 8 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $20.38. The target pricing ranges from a high forecast of $50.00 down to a low forecast of $3.00. [Atara Biotherapeutics (ATRA)](’s last closing price was $$4.645 which would put the average price target at $20.38. Here are 3rd party ratings for [ATRA](: - TipRanks.com: Hold - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 31% (78 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Is President Biden Finished Because of THIS?]( [32264b6c-866...](Polling shows the Biden administration is in big trouble. But what’s the REAL reason why Biden could resign in the next 30 days? According to Andrew Zatlin, a Bloomberg #1 ranked economist, the one issue which could trigger Biden’s resignation is surprising: It will likely NOT be related to inflation, rising gas prices, or cognitive health problems… [Go Here Now to Find Out The Surprising “Why” Biden Could Be Finished, How this New Crisis Could Play out With Disastrous Consequences for America…]( [click]([aff_i?offer_...] --------------------------------------------------------------- [Osisko Development, ODV]( Recent Analyst Action: Wayne Lam, analyst at RBC Capital, reiterates coverage on [Osisko Development (ODV)](in the Basic Materials sector with a Buy rating and a price target of $12.41 (1 week ago). - Recent Price: $5.75 - Average Analyst Price Target: $10.55 (83.30%) - Market Cap: $323.03M [TipRanks.com]( also reports that [Osisko Development](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.55. The target pricing ranges from a high forecast of $12.43 down to a low forecast of $7.96. [Osisko Development (ODV)](’s last closing price was $5.75 which would put the average price target at $10.54. Here are 3rd party ratings for [ODV](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 36% (162 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [TPI Composites, TPIC]( Recent Analyst Action: Stephen Gengaro, analyst at Stifel Nicolaus, reiterates coverage on [TPI Composites (TPIC)](in the Industrial Goods sector with a Hold rating and a price target of $21 (1 day ago). - Recent Price: $23.51 - Average Analyst Price Target: $19.50 (-17.06%) - Market Cap: $835.70M [TipRanks.com]( also reports that [TPI Composites](currently has 8 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.50. The target pricing ranges from a high forecast of $27.00 down to a low forecast of $13.00. [TPI Composites (TPIC)](’s last closing price was $23.51 which would put the average price target at $19.50. Here are 3rd party ratings for [TPIC](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Bottom 25% (190 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry?]( [a4f92c65-722...](You've never heard of this rare metal. But it's CRITICAL for our fighter jets, missiles, and military vehicles. The bad news is, Communist China has a MONOPOLY on this critical resource... [But Trump AND Biden's Executive Orders Could Change That, And Trigger A Boom For Investors](//trailer.web-view.net/Links/0X49C86E417739E17AF3243803BFB472B9C98A16E95A081ACFFC3BC9A906943CB14F8CA830007217B1CB184BE91E263B9E67C9223523E97B49001B444F7491C4D0F598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, Editor, MarketInsidersPress.com Market Insider Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketInsidersPress.com Sandpiper Marketing Group, LLC | | PO Box 407 | Mount Mourne | | North Carolina | 28123 | | United States | 8458030954 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software